Article
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery - 4 Oct 2022
Miyata Ryo, Hamaji Masatsugu, Kawaguchi Atsushi, Shimazu Yumeta, Ikeda Masaki, Ishikawa Masashi, Kayawake Hidenao, Menju Toshi, Kobayashi Masashi, Okumura Norihito, Sakaguchi Yasuto, Sonobe Makoto, Matsumoto Akira, Shoji Tsuyoshi, Katakura Hiromichi, Sumitomo Ryota, Huang Cheng-Long, Takahashi Mamoru, Aoyama Akihiro, Muranishi Yusuke, Kono Tomoya, Miyahara Ryo, Date Naoki, Fujinaga Takuji, Miyamoto Ei, Nakagawa Tatsuo, Fukada Takahisa, Sakai Hiroaki, Date Hiroshi
Abstract excerpt
OBJECTIVES: The aim of this study was to analyse the long-term survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma. METHODS: Using a multi-institutional database, we performed a retrospective chart review to identify all patients who had undergone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.